



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/505,693
Filing Date	April 21, 2005
First Named Inventor	Kurt Berlin
Art Unit	1634
Examiner Name	Katherine D. Salmon
Attorney Docket Number	47675-86

Sheet 1 of 6

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/KS/		US- 4683195	07-28-1987	Mullis et al.	
		US- 4683202	07-28-1987	Mullis	
		US- 4800159	01-24-1989	Mullis et al.	
		US- 5496699	03-05-1996	Sorenson	
		US- 5552277	09-03-1996	Nelson et al.	
		US- 5691146	11-25-1997	Mavrand	
		US- 5723591	03-03-1998	Livak et al.	
		US- 5876930	03-02-1999	Livak et al.	
		US- 5952170	09-14-1999	Stroun et al.	
		US- 6156504	12-05-2000	Gocke et al.	
		US- 6214556	04-10-2001	Olek et al.	
		US- 6228592	05-08-2001	Tsuji et al.	
		US- 6265171	07-24-2001	Herman et al.	
		US- 6331393	12-18-2001	Laird et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T*
		Country Code ² -Number ⁴ -Kind Code ⁵ (if known)				
/KS/		WO 95/00669	01-05-1995	Pharmacia Biotech AB		
		WO 95/15373	06-08-1995	McGill University		
		WO 95/16792	06-22-1995	Stroun et al.		
		WO 96/40995	12-19-1996	Trustees of Dartmouth College		
		WO 97/45560	12-04-1997	North Shore University Hospital Research Corp.		
		WO 97/46705	12-11-1997	Johns Hopkins University School of Medicine		
		WO 98/06980	03-05-1998	Johns Hopkins University School of Medicine		

Examiner Signature	/Katherine Salmon/	Date Considered	09/30/2008
-----------------------	--------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard St. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/506,693
		Filing Date	April 21, 2005
		First Named Inventor	Kurt Berlin
		Art Unit	1634
		Examiner Name	Katherine D. Salmon
		Attorney Docket Number	47675-86
Sheet	2	of	6

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.†	Foreign Patent Document Country Code ² -Number ³ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
/KS/		WO 98/56952	12-17-1998	University of Southern California		
↓		WO 99/28498	06-10-1999	Epigenomics GmbH		
		WO 00/70090	11-23-2000	University of Southern California		
		WO 02/072880	09-19-2002	Epigenomics AG		
NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ⁶
/KS/		ADORJAN et al., "Tumour class prediction and discovery by microarray-based DNA methylation analysis," Nucleic Acids Research, 2002, p. e21, Volume 30, No. 5 (9 pages)				
↓		AGATHANGGELOU et al., "Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours," Oncogene, 2001, pp. 1509-1515, Volume 20				
		AHRENDT et al., "Molecular Detection of Tumor Cells in Bronchoalveolar Lavage Fluid From Patients With Early Stage Lung Cancer," Journal of the National Cancer Institute, February 17, 1999, pp. 332-339, Volume 91, No. 4				
		ANKER et al., "Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients," Cancer and Metastasis Reviews, 1999, pp. 65-73, Volume 18				
		ANKER et al., "K-ras Mutations Are Found in DNA Extracted From the Plasma of Patients With Colorectal Cancer," Gastroenterology, 1997, pp. 1114-1120, Volume 112				
		BAYLIN et al., "Abnormal Patterns of DNA Methylation in Human Neoplasia: Potential Consequences for Tumor Progression," Cancer Cells, October 1991, pp. 383-390, Volume 3, No. 10				
		BOTEZATU et al., "Genetic Analysis of DNA Excreted in Urine: A New Approach for Detecting Specific Genomic DNA Sequences from Cells Dying in an Organism," Clinical Chemistry, 2000, pp. 1078-1084, Volume 46, No. 8				
		BRET et al., "Quantitation of blood plasma DNA as an index of in vivo cytotoxicity," Toxicology, 1990, pp. 283-292, Volume 61				
		BYUN et al., "Frequent Epigenetic Inactivation of RASSF1A by Aberrant Promoter Hypermethylation in Human Gastric Adenocarcinoma," Cancer Research, October 1, 2001, pp. 7934-7938, Volume 61				
		CAIRNS et al., "Molecular Detection of Prostate Cancer in Urine by GSTP1 Hypermethylation," Clinical Cancer Research, September 2001, pp. 2727-2730, Volume 7				
		CHEN et al., "Dermatofibroma is a clonal proliferative disease," Journal of Cutaneous Pathology, 2000, pp. 36-39, Volume 27				
↓		CHEN et al., "Microsatellite alterations in plasma DNA of small cell lung cancer patients," Nature Medicine, September 1996, pp. 1033-1035, Volume 2, No. 9				
Examiner Signature	/Katherine Salmon/			Date Considered	09/30/2008	

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 809. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-766-9199) and select option 2.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/506,693
		Filing Date	April 21, 2005
		First Named Inventor	Kurt Berlin
		Art Unit	1634
		Examiner Name	Katherine D. Salmon
		Attorney Docket Number	47675-88
Sheet	3	of	6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	?
/KS/		DE BUSTROS et al., "The short arm of chromosome 11 is a 'hot spot' for hypermethylation in human neoplasia," The Proceedings of the National Academy of Science, August 1988, pp. 5693-5697, Volume 85	
		DIVIACCO et al., "A novel procedure for quantitative polymerase chain reaction by coamplification of competitive templates," Gene, 1992, pp. 313-320, Volume 122	
		DONG et al., "Promoter Hypermethylation of Multiple Genes in Carcinoma of the Uterine Cervix," Clinical Cancer Research, July 2001, pp. 1982-1986, Volume 7	
		EADS et al., "Epigenetic Patterns in the Progression of Esophageal Adenocarcinoma," Cancer Research, April 15, 2001, pp. 3410-3418, Volume 61	
		EISENBERGER et al., "Diagnosis of Renal Cancer by Molecular Urinalysis," Journal of the National Cancer Institute, December 1, 1992, pp. 2028-2032, Volume 91, No. 23	
		ESTELLER et al., "A Gene Hypermethylation Profile of Human Cancer," Cancer Research, April 15, 2001, pp. 3225-3229, Volume 61	
		FEARON et al., "A Genetic Model for Colorectal Tumorigenesis," Cell, June 1, 1990, pp. 759-767, Volume 61	
		FEIL et al., "Methylation analysis on individual chromosomes: improved protocol for bisulphite genomic sequencing," Nucleic Acids Research, 1994, pp. 695-696, Volume 22, No. 4	
		FERLUGA, "Possible Organ and Age-Related Epigenetic Factors in Huntington's Disease and Colorectal Carcinoma," Medical Hypotheses, 1989, pp. 51-54, Volume 29	
		FOURNIE et al., "Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours," Cancer Letters, 1995, pp. 221-227, Volume 91	
		GARCIA et al., "Loss of p16 Protein Expression Associated with Methylation of the p16 ^{INK4A} Gene Is a Frequent Finding in Hodgkin's Disease," 1999, pp. 1453-1459, Volume 79, No. 12	
		GIACONA et al., "Cell-Free DNA in Human Blood Plasma: Length Measurements in Patients with Pancreatic Cancer and Healthy Controls," Pancreas, 1998, pp. 89-97, Volume 17, No. 1	
		GOESSL et al., "Microsatellite Analysis of Plasma DNA from Patients with Clear Cell Renal Carcinoma," Cancer Research, October 15, 1998, pp. 4728-4732, Volume 58	
		GONZALGO et al., "Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE), Nucleic Acids Research, 1997, pp. 2529-2531, Volume 25, No. 12	
		GRIGG et al., "Sequencing 5-Methylcytosine Residues in Genomic DNA," BioEssays, June 1994, pp. 431-436, Volume 16, No. 6	
		HANNA et al., "A Novel Alternative Approach for Prediction of Radiation Response of Squamous Cell Carcinoma of the Head and Neck," Cancer Research, March 15, 2001, pp. 2376-2380, Volume 61	
		HEID et al., "Real Time Quantitative PCR," Genome Research, 1996, pp. 988-994, Volume 6	
		HENGGEN, "Determining DNA concentrations and rescuing PCR primers," Trends in Biochemical Sciences, February 1994, pp. 93-94, Volume 19	

Examiner Signature	/Katherine Salmon/	Date	09/30/2008
		Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/506,693
		Filing Date	April 21, 2005
		First Named Inventor	Kurt Berlin
		Art Unit	1634
		Examiner Name	Katherine D. Salmon
		Attorney Docket Number	47675-86
Sheet	4	of	6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS); title of the article (when appropriate); title of the item (book, magazine, journal, serial, symposium, catalog, etc.); date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/KS/		HENGGEN, "Kli Wars," Trends in Biochemical Sciences, January 1994, pp. 46-47, Volume 19	
		HERMAN et al., "Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands," The Proceedings of the National Academy of Sciences, September 1996, pp. 9821-9826, Volume 93	
		HERMAN et al., "Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma," The Proceedings of the National Academy of Sciences, October 1994, pp. 8700-8704, Volume 91	
		HOLLIDAY, "The Inheritance of Epigenetic Defects," Science, October 9, 1987, pp. 163-170, Volume 238	
		HORNSTRA et al., "High resolution methylation analysis of the FMR1 gene trinucleotide repeat region in fragile X syndrome," Human Molecular Genetics, 1993, pp. 1659-1665, Volume 2, No. 10	
		JAHR et al., "DNA Fragments in the Blood Plasma of Cancer Patients: Quantitations and Evidence for Their Origin from Apoptotic and Necrotic Cells," Cancer Research, February 15, 2001, pp. 1659-1665, Volume 61	
		JONES, "DNA Methylation and Cancer," Cancer Research, February 1986, pp. 461-466, Volume 46	
		JONES et al., "The Role of DNA Methylation in Cancer," Advances in Cancer Research, 1990, pp. 1-23, Volume 54	
		KERSTING et al., "Differential Frequencies of p16 ^{INK4a} promoter Hypermethylation, p53 Mutation, and K-ras Mutation in Exfoliative Material Mark the Development of Lung Cancer in Symptomatic Chronic Smokers," Journal of Clinical Oncology, September 15, 2000, pp. 3221-3229, Volume 18, No. 18	
		KLAUCK et al., "Molecular genetic analysis of the FMR-1 gene in a large collection of autistic patients," Human Genetics, 1997, pp. 224-229, Volume 100	
		LABARCA et al., "A Simple, Rapid, and Sensitive DNA Assay Procedure," Analytical Biochemistry, 1980, pp. 344-352, Volume 102	
		LEE et al., "Monoclonal Endothelial Cell Proliferation is Present in Primary but not Secondary Pulmonary Hypertension," Journal of Clinical Investigation, March 1998, pp. 927-934, Volume 101, Number 5	
		LEE et al., "Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma," Transfusion, 2001, pp. 276-282, Volume 41	
		LEON et al., "Free DNA in the Serum of Cancer Patients and the Effect of Therapy," Cancer Research, March 1977, pp. 646-650, Volume 37	
		LO, "Molecular Testing of Urine: Catching DNA on the Way Out," Clinical Chemistry, 2000, pp. 1039-1040, Volume 46, No. 8	
		LO et al., "Quantitative Analysis of Fetal DNA in Maternal Plasma and Serum: Implications for Noninvasive Prenatal Diagnosis," American Journal of Human Genetics, 1996, pp. 768-775, Volume 62	
		MAEBO, "Plasma DNA Level as a tumor Marker in Primary Lung Cancer," The Japanese Journal of Thoracic Diseases, August 1990, pp. 1085-1091, Volume 28, No. 8	
V		MAKOS et al., "Distinct hypermethylation patterns occur at altered chromosome loci in human lung and colon cancer," The Proceedings of the National Academy of Sciences, March 1992, pp. 1929-1933, Volume 89	

Examiner Signature	/Katherine Salmon/	Date	09/30/2008
		Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/506,693
		Filing Date	April 21, 2005
		First Named Inventor	Kurt Berlin
		Art Unit	1634
		Examiner Name	Katherine D. Salmon
		Attorney Docket Number	47675-86
Sheet	5	of	6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-serial number(s), publisher, city and/or country where published.	T ²
/KS/		MAO et al., "Detection of Oncogene Mutations in Sputum Precedes Diagnosis of Lung Cancer," Cancer Research, April 1, 1994, pp. 1634-1637, Volume 54	
		MAO, "Genetic Alterations as Clonal Markers for Bladder Cancer Detection in Urine," Journal of Cellular Biochemistry, 1996, pp. 191-196, Volume 255	
		MAO et al., "Microsatellite alterations as clonal markers for the detection of human cancer," The Proceedings of the National Academy of Sciences, October 1994, pp. 9871-9875, Volume 91	
		MARTIN et al., "Genomic sequencing indicates a correlation between DNA hypomethylation in the 5' region of the p52 gene and its expression in human breast cancer cell lines," Gene, 1995, pp. 261-264, Volume 157	
		MARUYAMA et al., "Aberrant Promoter Methylation Profile of Bladder Cancer and Its Relationship to Clinicopathological Features," Cancer Research, December 15, 2001, pp. 8659-8663, Volume 61	
		NAKAO et al., "Rapid and Reliable Quantification of Minimal Residual Disease in Acute Lymphoblastic Leukemia Using Rearranged Immunoglobulin and T-Cell Receptor Loci by LightCycler Technology," Cancer Research, June 15, 2000, pp. 3281-3289, Volume 60	
		OHTANI-FUJITA et al., "CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene," Oncogene, 1993, pp. 1063-1067, Volume 8	
		OLEK et al., "A modified and improved method for bisulphite based cytosine methylation analysis," Nucleic Acids Research, 1996, pp. 5064-5066, Volume 24, No. 24	
		OLEK et al., "The pre-implantation ontogeny of the H19 methylation imprint," Nature Genetics, November 1997, pp. 275-276, Volume 17	
		PALMISANO et al., "Predicting Lung Cancer by Detecting Aberrant Promoter Methylation in Sputum," Cancer Research, November 1, 2000, pp. 5954-5958, Volume 60	
		REIN et al., "Identifying 5-methylcytosine and related modifications in DNA genomes," Nucleic Acids Research, 1998, pp. 2255-2264, Volume 26, No. 10	
		SACCOMANNO et al., "Development of Carcinoma of the Lung as Reflected in Exfoliated Cells," Cancer, January 1974, pp. 256-270, Volume 33	
		SANCHEZ-CESPEDES et al., "Gene Promoter Hypermethylation in Tumors and Serum of Head and Neck Cancer Patients," Cancer Research, February 15, 2000, pp. 892-895, Volume 60	
		SANGER et al., "DNA sequencing with chain-terminating inhibitors," The Proceedings of the National Academy of Sciences, December 1977, pp. 5463-5467, Volume 74, No. 12	
		SHAPIRO et al., "Determination of Circulating DNA Levels in Patients with Benign or Malignant Gastrointestinal Disease," Cancer, 1983, pp. 2116-2120, Volume 51	
		SHAPIRO et al., "Specific Deamination of RNA by Sodium Bisulphite," Nature, September 5, 1970, pp. 1047-1048, Volume 227	
		SORENSEN et al., "Soluble Normal and Mutated DNA Sequences from Single-Copy Genes in Human Blood," Cancer Epidemiology, Biomarkers & Prevention, January/February 1994, pp. 67-71, Volume 3	

Examiner Signature	/Katherine Salmon/	Date	09/30/2008
		Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

[illegible]

Examiner Signature	/Katherine Salmon/	Date Considered	09/30/2008
-----------------------	--------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible.⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.